Damora Therapeutics, Inc. is trading 5.6% down at $21.09 as risk-off sentiment pressures smaller biotechnology names and high-growth risk assets.
- The stock is extending a steep multi-day decline from recent closing levels above $24.
- There are no new company-specific headlines or SEC filings on June 4, 2026, to explain the downward move.
- Shares appear to be sliding alongside the broader biotechnology sector despite mixed performance across major market indices.